UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

_______________________________

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

__________________________________

 

Date of Report (Date of earliest event reported): March 28, 2012

 

 

  NEUROMETRIX, INC.  

(Exact name of registrant as specified in charter)

 

Delaware

001-33351

04-3308180

(State or other jurisdiction
of incorporation)		 (Commission File Number) (IRS Employer
Identification No.)

62 Fourth Avenue, Waltham, Massachusetts           02451
(Address of principal executive offices)             (Zip Code)

 

(781) 890-9989
(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

 

Item 8.01 Other Events - Wal-Mart Canada Corp. Purchase Order

 

On March 28, 2012, NeuroMetrix, Inc. (NASDAQ: NURO) (the “Company”) accepted a purchase order from Wal-Mart Canada Corp. (“Wal-Mart Canada”), a subsidiary of Wal-Mart Stores, Inc. (NYSE: WMT), which operates approximately 100 pharmacies across Canada. The purchase order covers the delivery of NC-stat DPNCheck devices and biosensors for use by health care professionals in 91 Wal-Mart Canada pharmacies for testing persons with diabetes for diabetic peripheral neuropathy (DPN). The Company will provide training to Wal-Mart Canada’s pharmacy personnel during April. The purchase order has a total value of approximately $150,000.

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    NEUROMETRIX, INC.  
     
     
Date: April 2, 2012 /s/ THOMAS T. HIGGINS  
    Thomas T. Higgins  
    Senior Vice President, Chief Financial Officer  
    and Treasurer